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Be a Target to Guide
Anticoagulation Treatment
in Patients With Low-Risk
Atrial Fibrillation to Reduce
Cognitive Impairment?In a comprehensive study by Gaita et al. (1) on the prevalence of
silent cerebral ischemia (SCI) assessed by cerebral magnetic reso-
nance in patients with paroxysmal and persistent atrial ﬁbrillation
(AF), it was shown that at least 1 area of SCI was observed in most
patients with paroxysmal and persistent AF (89% and 92%,
respectively) compared with 46% in controls without AF.
A striking ﬁnding of this study is that approximately half of the
patients without AF (controls) had at least an area of SCI. Other
cardioembolic or atheroembolic sources (i.e., cerebral embolization
by clots passing through a patent foramen ovale or material from
nonstenotic carotid plaques) could explain the presence of SCI in
such a high number of controls (2–4). The current study excluded
patients with carotid stenosis of >70%, but as observed in large-
scale trials on asymptomatic patients, there was no clear relationbetween the degree of stenosis and risk of cerebral embolization (5),
and most patients had bilateral noncritical plaques. Thus, a po-
tential limitation of this interesting study is that it did not control
for these additional factors that could account for SCI. Further-
more, hypertension is 1 of the major risk factors of cerebral white
matter lesions (6), and could also explain the high number of
lesions observed in the group without AF. Thus, SCI must be
considered a relatively nonspeciﬁc marker of embolic cerebral injury
secondary to AF. Nevertheless, the investigators demonstrated
a signiﬁcant link between the extent of SCI areas and the degree
of cognitive impairment in patients with AF. In the group of
patients with paroxysmal AF, a large proportion of patients
received aspirin (37.8%) or no antiplatelet agent and/or oral anti-
coagulation (OAC) treatment (18.9%); thus, it would be of great
interest to know in this group of patients whether OAC was
associated with a decreased number of SCI areas compared with
patients taking aspirin or not receiving treatment. In a previous
study, aspirin use was associated with a reduced number of cerebral
white matter lesions (7). Currently, patients with AF (age <65
years and CHA2DS2-VASc score ¼ 0) are not considered for
OAC due to the low risk of embolic stroke (8). Nevertheless, OAC
could also prevent SBI in these low-risk patients. If a lower
occurrence of SBI is associated with OAC compared with aspirin,
that could suggest that OAC may be more effective to prevent
cognitive impairment associated with paroxysmal AF (9) in the
long term, even in patients who are at low risk for embolic stroke.
We believe that further trials able to demonstrate reduction of
SCI beyond the reduction of risk of embolic stroke should be
planned in the future, particularly in the era of new OAC, which
has been associated with a lower risk of bleeding. Finally, the
reduction of cognitive impairment associated with the longitudinal
quantitative evaluation of white matter lesions could be a new mid-
to long-term clinical endpoint to be addressed in the treatment of
AF patients.*Enrico Ammirati, MD
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Be a Target to Guide
Anticoagulation Treatment
in Patients With Low-Risk
Atrial Fibrillation to Reduce
Cognitive Impairment?As commented on by Dr. Ammirati and colleagues, the recent
evidence (1) that the prevalence of silent cerebral ischemia (SCI)
in patients with paroxysmal and persistent atrial ﬁbrillation (AF)
and controls in sinus rhythm implies several clinically relevant
issues.
The ﬁnding that approximately half of the controls presented at
least an area of SCI is strongly hypothesis-generating. In contrast,
the prevalence of other cardioembolic sources, such as patent fo-
ramen ovale or nonstenotic carotid plaques material, should not
be stratiﬁed differently within cases and controls; therefore, not
biasing the main results of the study.
The question of whether SCI represents a target for oral anti-
coagulation (OAC) to prevent cognitive impairment is crucial. Risk
stratiﬁcation, to date, relies on clinical scores (CHA2DS2-VASc
score) based on symptomatic cerebral events only, which is
fallacious.
The occurrence of cerebrovascular events in AF patients, despite
a low-risk score, is unfortunately not unusual (2), and warrantsintroduction of “new” markers, such as left atrial appendage
morphology (3,4) and speciﬁc echocardiographic parameters (5).
Limited literature has assessed whether antiaggregants and/or
OAC may prevent or reduce SCI. One small study (6) suggested
that aspirin attenuates SCI incidence in AF patients, preventing
events in early stages of AF-related cerebral damage, and conse-
quently, cognitive decline. However, this option is not recom-
mended due to the detrimental effects of antiaggregants on
bleeding (7). We fully agree with Ammirati et al. that further
prospective randomized trials are needed to evaluate the possible
reduction of SCI by OAC. In the meantime, aggressive rhythm
control strategy is mandatory to prevent clinical and SCI areas by
restoring and maintaining sinus rhythm.*Fiorenzo Gaita, MD, Prof
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